Delivering a STINging blow to small cell lung cancer via synergistic inhibition of DNA-damage response and immune-checkpoint pathways

Abstract

Small cell lung cancer (SCLC) has demonstrated modest responses to immune-checkpoint blockade despite harboring a high mutational burden. In this issue, Sen and colleagues show remarkable synergy between inhibition of the DNA-damage response and the PD-1 axis, resulting in striking tumor regressions in SCLC mouse models.